

Authority: Section 3(c)(10) of the Export-Import Bank Act of 1945, as amended (12 U.S.C. 635a(c)(10)).

Deidre Hodge,

Assistant Corporate Secretary.

[FR Doc. 2025–16406 Filed 8–26–25; 8:45 am]

BILLING CODE 6690–01–P

EXPORT-IMPORT BANK

[Public Notice: EIB–2025–0015]

Application for Final Commitment for a Long-Term Loan or Financial Guarantee in Excess of \$100 Million: AP300024XX

AGENCY: Export-Import Bank of the United States.

ACTION: Notice.

SUMMARY: This Notice is to inform the public, in accordance with the Export-Import Bank Act of 1945, as amended, the Export-Import Bank of the United States (“EXIM”) has received an application for final commitment for a long-term loan or financial guarantee in excess of \$100 million. Comments received within the comment period specified below will be presented to the EXIM Board of Directors prior to final action on this Transaction.

DATES: Comments must be received on or before *September 22, 2025* to be assured of consideration before final consideration of the transaction by the Board of Directors of EXIM.

ADDRESSES: Comments may be submitted through *Regulations.gov* at *www.regulations.gov*. To submit a comment, enter EIB–2025–0015 under the heading “Enter Keyword or ID” and select Search. Follow the instructions provided at the Submit a Comment screen. Please include your name, company name (if any) and EIB–2025–0015 on any attached document.

SUPPLEMENTARY INFORMATION:

Reference: AP300024XX.

Purpose and Use:

Brief description of the purpose of the transaction: to support the export of U.S.-manufactured commercial jet aircraft to Turkey.

Brief non-proprietary description of the anticipated use of the items being exported: to provide domestic and international passenger air transportation.

To the extent that EXIM is reasonably aware, the item(s) being exported are not expected to produce exports or provide services in competition with the exportation of goods or provision of services by a United States industry.

Parties:

Principal Supplier: The Boeing Company.

Obligor: Gunes Ekspres Havacilik, AS.

Guarantor(s): n/a.

Description of Items Being Exported: Commercial jet aircraft.

Information on Decision: Information on the final decision for this transaction will be available in the “Board Agenda and Meeting Minutes” on *https://www.exim.gov/news/meeting-minutes*.

Confidential Information: Please note that this notice does not include confidential or proprietary business information; information which, if disclosed, would violate the Trade Secrets Act; or information which would jeopardize jobs in the United States by supplying information that competitors could use to compete with companies in the United States.

Authority: Section 3(c)(10) of the Export-Import Bank Act of 1945, as amended (12 U.S.C. 635a(c)(10)).

Deidre Hodge,

Assistant Corporate Secretary.

[FR Doc. 2025–16405 Filed 8–26–25; 8:45 am]

BILLING CODE 6690–01–P

FEDERAL RESERVE SYSTEM

Change in Bank Control Notices; Acquisitions of Shares of a Bank or Bank Holding Company

The notificants listed below have applied under the Change in Bank Control Act (Act) (12 U.S.C. 1817(j)) and § 225.41 of the Board’s Regulation Y (12 CFR 225.41) to acquire shares of a bank or bank holding company. The factors that are considered in acting on the applications are set forth in paragraph 7 of the Act (12 U.S.C. 1817(j)(7)).

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal Reserve Bank and from the Board’s Freedom of Information Office at *https://www.federalreserve.gov/foia/request.htm*. Interested persons may express their views in writing on the standards enumerated in paragraph 7 of the Act.

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential,

contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Ann E. Misback, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551–0001, not later than September 11, 2025.

A. Federal Reserve Bank of Chicago (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690–1414.

Comments can also be sent electronically to

Comments.applications@chi.frb.org:

1. *The Lenore M. McCarter*

Declaration of Trust, Lenore M. McCarter, as trustee, both of Snowmass, Colorado; to retain voting shares of F.N.B.C. of LaGrange, Inc., and thereby indirectly retain voting shares of FNBC Bank and Trust, both of LaGrange, Illinois.

Board of Governors of the Federal Reserve System.

Michele Taylor Fennell,

Associate Secretary of the Board.

[FR Doc. 2025–16414 Filed 8–26–25; 8:45 am]

BILLING CODE P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Office of the Secretary

Statement of Delegation of Authority

Notice is hereby given that I have delegated to the Director of the Office for Civil Rights (OCR) the following authorities vested in the Secretary of Health and Human Services:

1. The authority under section 543 of the Public Health Service Act, as amended by section 3221 of the Coronavirus Aid, Relief, and Economic Security (CARES) Act (Pub. L. 116–136), 42 U.S.C. 290dd–2, and its implementing regulation, 42 CFR part 2, to the extent that these actions pertain to the confidentiality of substance use disorder patient records, to:

A. Impose civil money penalties under section 1176 of the Social Security Act, as amended, for failures to comply with requirements under that section;

B. Enter into resolution agreements, monetary settlements, and corrective action plans, as appropriate, to resolve indications of noncompliance with requirements of that section; and

C. Issue subpoenas requiring the attendance and testimony of witnesses and the production of any evidence that relates to any matter under investigation or compliance review for failure to comply with requirements of that section.

2. The authority under section 543 of the Public Health Service Act, as amended by section 3221 of the CARES Act, to administer the regulation, "Confidentiality of Substance Use Disorder Patient Records," at 42 CFR part 2, and to make decisions regarding the interpretation, implementation, and enforcement of these requirements.

General Provisions

This delegation supersedes any prior delegations.

This authority may be redelegated by the Director of OCR.

I hereby affirm and ratify any actions taken by the Director of OCR or their subordinates which involved the exercise of the authority delegated herein prior to the effective date of this delegation.

Effective Date

This delegation is effective upon the date of signature.

Authority

42 U.S.C. 290dd-2; 42 U.S.C. 1320d-5; 42 CFR part 2.

Dated: August 25, 2025.

Robert F. Kennedy, Jr.

Secretary, Department of Health and Human Services.

[FR Doc. 2025-16391 Filed 8-26-25; 8:45 am]

BILLING CODE 4153-01-P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government Owned Inventions Available for Licensing or Collaboration: RFXP1 AGONISTS

AGENCY: National Institutes of Health, HHS.

ACTION: Notice.

SUMMARY: The National Center for Advancing Translational Sciences (NCATS), an institute of the National Institutes of Health (NIH), Department of Health and Human Services (HHS), is giving notice of the licensing opportunities for the inventions listed below, which are owned by an agency of the U.S. Government, Florida International University (FIU), and University of South Florida (USF). The NCATS has taken the lead in both

patenting and licensing via consolidation of rights under an Inter Institutional Agreement (IIA). The inventions are available for licensing and collaboration to achieve expeditious commercialization results of federally funded research and development.

FOR FURTHER INFORMATION CONTACT:

Inquiries related to these licensing or collaboration opportunities should be directed to: Jasmine Kalsi, M.S., Licensing and Patenting Manager, Office of Strategic Alliances (OSA), NCATS, Email: jasmine.kalsi@nih.gov or Phone: 301-435-0129. Respondents will be required to submit an "Application for License to Public Health Service Inventions." An executed CDA will be required to receive copies of the patent applications.

SUPPLEMENTARY INFORMATION: NIH seeks to ensure that technologies developed by NIH and its partners are expeditiously commercialized and brought to practical use. NCATS is actively seeking a licensing partner to facilitate the development and commercialization of a technology or small molecule compounds that are in an early phase of development for therapeutic interventions for cancers, fibrotic and vascular disease including but not limited to breast cancer, solid tumors, atherosclerosis, and liver fibrosis.

NCATS in collaboration with Florida International University (FIU) and University of South Florida (USF) has identified low molecular weight, highly potent, and efficient full RXFP1 agonists with low cytotoxicity. The identification and characterization of these compounds may lead to the development of a new class of cost-effective drugs for the treatment of numerous cancers, fibrotic, and vascular disorders.

It is well documented in literature that activation of RXFP1 by relaxin induces: (1) up-regulation of the endothelin system which leads to vasodilation; (2) extracellular matrix remodeling through regulation of collagen deposition, cell invasiveness, proliferation, and overall tissue homeostasis; (3) a moderation of inflammation by reducing levels of inflammatory cytokines, such as TNF- α and TGF- β ; and (4) angiogenesis by activating transcription of VEGF.

The present invention is directed to novel relaxin receptor (RFXP1 receptor) small molecule agonists useful for treating relaxin-related disorders including fibrosis, certain cancers, vascular calcifications, including atherosclerosis, and heart failure. The RFXP1 agonists of this invention

possess a number of advantages not found in earlier RFXP1 agonists. These properties include, for example, improved bioavailability, low toxicity, and better activity in RXFP1-dependent biological functional assays.

The development of small-molecule agonists of RXFP1 would have numerous benefits and will allow investigating additional therapeutic applications where chronic administration is required. NCATS has identified a series of small-molecule agonists of RXFP1 which are potent, highly selective, easy to synthesize, and with reasonable metabolic and physical properties. Our molecules display similar efficacy as the natural hormone in several functional assays. Mutagenesis studies have mapped the specific regions responsible for relaxin receptor activation by these compounds to an allosteric site on the receptor. Finally, these compounds display good in vivo pharmacokinetic properties and are currently being evaluated in vivo.

This Notice is in accordance with 35 U.S.C. 209 and 37 CFR part 404.

NIH Reference Number: E-145-2024-0.

Product Type: Therapeutics.

Therapeutic Area(s): Reproductive Health, Pulmonology, Oncology, Geriatrics, Dermatology, Cardiology.

Potential Commercial Applications:

- Vascular health
 - Fibrotic diseases
 - Cancers
 - Human reproductive health
- Competitive Advantages:*
- Potent and highly selective
 - Bioavailable with excellent exposure

- Easy to synthesize and scale-up

Publication:

"Anti-apoptotic and Matrix Remodeling Actions of a Small Molecule Agonist of the Human Relaxin Receptor, ML290 in Mice With Unilateral Ureteral Obstruction." Ng HH, Soula M, Rivas B, Wilson KJ, Marugan JJ, Agoulnik AI. *Front Physiol.* 2021 Jul 7.

Therapeutic effects of a small molecule agonist of the relaxin receptor ML290 in liver fibrosis. Kaftanovskaya EM, Ng HH, Soula M, Rivas B, Myhr C, Ho BA, Cervantes BA, Shupe TD, Devarasetty M, Hu X, Xu X, Patnaik S, Wilson KJ, Barnaeva E, Ferrer M, Southall NT, Marugan JJ, Bishop CE, Agoulnik IU, Agoulnik AI. *FASEB J.* 2019 Nov.

Optimization of the first small-molecule relaxin/insulin-like family peptide receptor (RFXP1) agonists: Activation results in an antifibrotic gene expression profile. Wilson KJ, Xiao J, Chen CZ, Huang Z, Agoulnik IU, Ferrer